Literature DB >> 27861837

Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.

Dawn C Buse1, Michael L Reed2, Kristina M Fanning2, Tobias Kurth3, Richard B Lipton4.   

Abstract

BACKGROUND: Though migraine, particularly migraine with aura, is a cardiovascular (CV) risk factor, the scope and distribution of cardiovascular disease in representative samples of people with migraine are not known. This is important because many widely used acute migraine treatments, including triptans, ergot alkaloids, and nonsteroidal anti-inflammatory drugs, carry precautions, warnings, or contraindications for use in persons with CV disease.
OBJECTIVES: To assess the scope and distribution of cardiovascular events, conditions, and procedures in persons with episodic migraine in a representative sample of the US population, using data from the American Migraine Prevalence and Prevention (AMPP) Study.
METHODS: Eligible subjects completed the 2009 AMPP survey, met ICHD-3beta criteria for migraine, and had a headache frequency of less than 15 days per month (episodic migraine). A survey on cardiovascular events (ie, myocardial infarction), conditions (ie, angina), and procedures (ie, carotid endarterectomy) was adopted from the Women's Health Study and the Physician's Health Studies. Cardiovascular events and conditions were defined by participant reports of having both experienced and received a physician diagnosis for a particular event or condition. The distribution of CV events, conditions, and procedures was summarized for the entire migraine sample and in groups defined by gender and age (22-39, 40-59, and ≥60). To assess the numbers of persons with episodic migraine in the US, we applied age and gender stratified estimates of migraine prevalence to the 2015 Census data. To estimate the number of cardiovascular events, conditions, and procedures in the US migraine population, we applied age and gender stratified event rates to the number of persons with episodic migraine in each stratum.
RESULTS: The 2009 AMPP Study survey was returned by 11,792 study participants out of 16,983 (64.9% response rate), including 6723 individuals who met study criteria for episodic migraine (5227 women and 1496 men). Among 22-39 year olds with episodic migraine, 3.4% reported having received a physician diagnosis of CV events or conditions and 1.1% reported undergoing CV related procedures. Among 40-59 year olds, 10.2% reported having received a physician diagnosis of CV events or conditions and 3.5% reported CV related procedures. For those age 60 or older, 22.3% reported CV events or conditions and 8.8% reported CV procedures. Prevalence of events, conditions, and procedures was higher in men than women and also in older age groups. However, the absolute number of CV events, procedures, and conditions was greater for women than men due to the higher population prevalence of episodic migraine in women. We projected that 2.0 million women and 665,000 men in the US had episodic migraine and a history of one or more CV event, condition, or procedure. By age group, it is estimated that 579,000 among those aged 22-39, 1.37 million of those aged 40-59, and 696,000 of those 60 and older with episodic migraine have ever had at least one CV event, procedure, or condition.
CONCLUSION: Based on these analyses, we estimate that there are roughly 2.6 million people with episodic migraine aged 22 and older in the US with one or more prior CV event, condition, or procedure. For this group, cardiovascular contraindications to many migraine-specific acute migraine therapies may make treatment challenging.
© 2016 American Headache Society.

Entities:  

Keywords:  AMPP study; cardiovascular; episodic migraine; myocardial infarction; stroke; triptan

Mesh:

Year:  2016        PMID: 27861837     DOI: 10.1111/head.12962

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  15 in total

1.  Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial.

Authors:  Henner Hanssen; Alice Minghetti; Stefano Magon; Anja Rossmeissl; Athina Papadopoulou; Christopher Klenk; Arno Schmidt-Trucksäss; Oliver Faude; Lukas Zahner; Till Sprenger; Lars Donath
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

2.  Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Authors:  Peter J Goadsby; Linda A Wietecha; Ellen B Dennehy; Bernice Kuca; Michael G Case; Sheena K Aurora; Charly Gaul
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

3.  Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Authors:  Messoud Ashina; Peter J Goadsby; Uwe Reuter; Stephen Silberstein; David Dodick; Gregory A Rippon; Jan Klatt; Fei Xue; Victoria Chia; Feng Zhang; Sunfa Cheng; Daniel D Mikol
Journal:  Cephalalgia       Date:  2019-05-30       Impact factor: 6.292

4.  Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.

Authors:  Erin Gautier Doty; John H Krege; Leah Jin; Joel Raskin; Rashmi B Halker Singh; Kavita Kalidas
Journal:  Cephalalgia       Date:  2019-07-03       Impact factor: 6.292

5.  Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Authors:  Eloísa Rubio-Beltrán; Alejandro Labastida-Ramírez; Kristian A Haanes; Antoon van den Bogaerdt; Ad J J C Bogers; Eric Zanelli; Laurent Meeus; A H Jan Danser; Michael R Gralinski; Peter B Senese; Kirk W Johnson; Joseph Kovalchin; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

6.  Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.

Authors:  Kerry Knievel; Andrew S Buchanan; Louise Lombard; Simin Baygani; Joel Raskin; John H Krege; Li Shen Loo; Mika Komori; Joshua Tobin
Journal:  Cephalalgia       Date:  2019-11-19       Impact factor: 6.292

Review 7.  Headache as a Neurologic Manifestation of Systemic Disease.

Authors:  Alexandra N Cocores; Teshamae S Monteith
Journal:  Curr Treat Options Neurol       Date:  2022-03-18       Impact factor: 3.972

8.  Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.

Authors:  Juliana H VanderPluym; Rashmi B Halker Singh; Meritxell Urtecho; Allison S Morrow; Tarek Nayfeh; Victor D Torres Roldan; Magdoleen H Farah; Bashar Hasan; Samer Saadi; Sahrish Shah; Rami Abd-Rabu; Lubna Daraz; Larry J Prokop; Mohammad Hassan Murad; Zhen Wang
Journal:  JAMA       Date:  2021-06-15       Impact factor: 56.272

9.  Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Authors:  Bernice Kuca; Stephen D Silberstein; Linda Wietecha; Paul H Berg; Gregory Dozier; Richard B Lipton
Journal:  Neurology       Date:  2018-11-16       Impact factor: 9.910

10.  Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data.

Authors:  David W Dodick; Anand S Shewale; Richard B Lipton; Seth J Baum; Steven C Marcus; Stephen D Silberstein; Jelena M Pavlovic; Nathan L Bennett; William B Young; Hema N Viswanathan; Jalpa A Doshi; Howard Weintraub
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.